


Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients

Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19

ABX464 in Phase 2a Trials for RA

Researchers Give Update on Janus Kinase (JAK) Inhibitors

Risankizumab & Apremilast Come to Market in Canada

Phase 3 Results for Olokizumab in RA Patients
Low-Dose Methotrexate Can Cause Adverse Effects

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 21
- Next Page »